title: [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
abstract: To study the efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 7 cases with FLT3-ITD positive AML have received allo-HSCT in our department from May 2013 to January 2015. Six cases were administrated with sorafenib after hematopoietic reconstruction. Another patient relapsed on day 192 past allo-HSCT, then she started to use sorafenib after remission of re-induction regimens. Five patients survived. The median progression free survival was 280(126-366)day. This study suggests that sorafenib might prevent relapse past allo-HSCT and improve survival in patients with FLT3-ITD positive AML.
authors.affiliation: Department of Haematology, Henan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Y L
authors.initials: YL
authors.lastname: Zu
authors.forename: Y L
authors.initials: YL
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: L J
authors.initials: LJ
authors.lastname: Han
authors.forename: H F
authors.initials: HF
authors.lastname: Zhao
authors.forename: R R
authors.initials: RR
authors.lastname: Gui
authors.forename: Y J
authors.initials: YJ
authors.lastname: Hou
authors.forename: Y P
authors.initials: YP
authors.lastname: Song
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000517:prevention & control* / Q000601:surgery; D008297:Male; D009154:Mutation; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D055502:Secondary Prevention; D000077157:Sorafenib; D015996:Survival Rate; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000187:drug effects / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3